REMICADE Treated Patients Experienced Rapid And Substantial Improvement In Psoriasis In Critical Regions Of Body

Data from an integrated analysis of three randomized, placebo-controlled trials showed patients with moderate to severe plaque psoriasis receiving REMICADE(R) (infliximab) achieved a consistently high level of skin clearance in each of the four body regions (head, trunk, lower and upper extremities) as measured by the Psoriasis Area Severity Index (PASI).

More: continued here

Filed under: Clinical Trials on February 7th, 2008